Wuhan Institute of Biological Products

Wuhan Institute of Biological Products Co., Ltd. (abbreviated as Sinopharm China National Biotec Wuhan Institute of Biological Products or Wuhan Institute of Biological Products) was founded in 1950 and is now affiliated with China National Biotec Group Co., Ltd., under China National Pharmaceutical Group Co., Ltd. (Sinopharm), which is supervised by the State-owned Assets Supervision and Administration Commission of the State Council. It is a large high-tech enterprise integrating production, education, research, and sales of biological products, and one of the major bases for biological product R&D, production, and supply in China. Sinopharm China National Biotec Wuhan Institute of Biological Products covers an area of approximately 542 mu, with a registered capital of 1.664 billion RMB and total assets exceeding 3 billion RMB. It currently has 995 employees, 76% of whom hold bachelor's degrees or above, and 32% are scientific and technical personnel, including 272 employees with master's or doctoral degrees and 284 with intermediate or senior professional titles. It is one of the first units authorized to confer doctoral and master's degrees in China and the only authorized doctoral degree-granting unit in the biological product industry. In 2010, it was approved to establish a post-doctoral scientific research workstation. Over the years, it has trained nearly a thousand senior biotechnology professionals, many of whom hold senior management or core important positions in nearly a hundred biological product-related enterprises nationwide. Since its founding 70 years ago, Wuhan Institute of Biological Products has been committed to the development of the biomedical industry with the spirit of unity, progress, pragmatism, and innovation, striving to make due contributions to human health. With the corporate philosophy of "Caring for life, safeguarding health" and the quality policy of "Product quality is the life of the enterprise, and the users are our own family members," it strictly adheres to the requirements of the Chinese Pharmacopoeia and the Good Manufacturing Practice for Pharmaceutical Products (GMP) and has established a comprehensive quality management system. All main product production lines have obtained the "Drug GMP Certificate" issued by the drug regulatory authorities, with complete equipment and facilities, advanced technology, and first-class product quality. Wuhan Institute of Biological Products shoulders the important task of producing, developing, and supplying biological products needed for national health (including vaccines, therapeutic products, and diagnostic reagents). Among the 11 varieties of national immunization program vaccines, it undertakes the production and supply of 5, ranking first in the country in terms of categories. It holds 60 drug approval numbers and has 8 main marketed products (Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine (Adsorbed), Enterovirus Type 71 Inactivated Vaccine, Japanese Encephalitis Live Attenuated Vaccine, Group A Meningococcal Polysaccharide Vaccine, Diphtheria and Tetanus Combined Vaccine (Adsorbed), Tetanus Vaccine (Adsorbed), Leptospira Vaccine, and Influenza Virus Split Vaccine (Quadrivalent)), with an annual production capacity of over 170 million doses. Among them, the Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine (Adsorbed) has a domestic market share of over 80%, the Japanese Encephalitis Live Attenuated Vaccine has a share of 50%, and four vaccines, including the Diphtheria and Tetanus Combined Vaccine (Adsorbed), are currently exclusively supplied domestically. The national Class I innovative vaccine, Enterovirus Type 71 Inactivated Vaccine, is the world's first marketed hand, foot, and mouth disease vaccine, and for the first time achieved the development of international standards for Chinese-led vaccines, providing a "yardstick" for the international application of vaccines. Since its launch, this product has generated sales revenue of nearly 2 billion RMB in three years, and its market share has quickly reached over 30%, reducing the incidence of severe hand, foot, and mouth disease in China by 98%. The company's revenue in 2019 was approximately 1.2 billion RMB. During the "14th Five-Year Plan" period, the compound annual growth rate is expected to exceed 30%, with annual revenue expected to reach over 5 billion RMB by the end of the period.
Wuhan Institute of Biological Products has two national engineering centers: the "National Engineering Technology Research Center for Combined Vaccines" and the "National and Local Joint Engineering Research Center for Biological Products." It also has the "Rabies Virus Street Laboratory" designated by the health authorities and the "Drug Technology Innovation Platform" under the Major New Drug Creation program. Over the past decade, by building three major scientific research platforms—bioreactors, combined vaccines, and humanized antibodies—it has increased scientific investment, optimized resource allocation, developed core technologies, accelerated independent innovation, and undertaken 22 national scientific research projects and 10 provincial and municipal scientific research projects. It has applied for 32 independent intellectual property rights for inventions and obtained 11. Currently, the company has 16 products in research, including 5 national Class I innovative drugs. In 2020, with the support of the Hubei Provincial Science and Technology Department, it was approved to build the "Hubei Provincial Vaccine Technology Innovation Center," with plans to invest 2 billion RMB in scientific research and 3.35 billion RMB in the expansion and upgrading of hardware facilities for the industrialization of scientific research results, providing strong support for China's infectious disease prevention and public health system construction.